Share-based Payment Arrangement, Expense of BIOCRYST PHARMACEUTICALS INC from 31 Dec 2012 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
BIOCRYST PHARMACEUTICALS INC quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2012 to 30 Sep 2025.
  • BIOCRYST PHARMACEUTICALS INC Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $18,601,000, a 7.8% increase year-over-year.
  • BIOCRYST PHARMACEUTICALS INC Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $82,612,000, a 36% increase year-over-year.
  • BIOCRYST PHARMACEUTICALS INC annual Share-based Payment Arrangement, Expense for 2024 was $65,413,000, a 18% increase from 2023.
  • BIOCRYST PHARMACEUTICALS INC annual Share-based Payment Arrangement, Expense for 2023 was $55,615,000, a 24% increase from 2022.
  • BIOCRYST PHARMACEUTICALS INC annual Share-based Payment Arrangement, Expense for 2022 was $44,701,000, a 29% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

BIOCRYST PHARMACEUTICALS INC Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $82,612,000 $18,601,000 +$1,352,000 +7.8% 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $81,260,000 $21,304,000 +$8,131,000 +62% 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $73,129,000 $21,368,000 +$7,716,000 +57% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $65,413,000 $21,339,000 +$4,851,000 +29% 01 Oct 2024 31 Dec 2024 10-K 25 Feb 2025 2024 FY
Q3 2024 $60,562,000 $17,249,000 +$4,970,000 +40% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025 2025 Q3
Q2 2024 $55,592,000 $13,173,000 +$332,000 +2.6% 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025 2025 Q2
Q1 2024 $55,260,000 $13,652,000 -$355,000 -2.5% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 $55,615,000 $16,488,000 01 Oct 2023 31 Dec 2023 10-K 25 Feb 2025 2024 FY
Q3 2023 $12,279,000 01 Jul 2023 30 Sep 2023 10-Q 05 Nov 2024 2024 Q3
Q2 2023 $12,841,000 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $14,007,000 +$4,406,000 +46% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q1 2022 $9,601,000 +$4,122,000 +75% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023 2023 Q1
Q1 2021 $5,479,000 +$2,725,000 +99% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q1 2020 $2,754,000 -$563,000 -17% 01 Jan 2020 31 Mar 2020 10-Q 07 May 2021 2021 Q1
Q1 2019 $3,317,000 +$414,000 +14% 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020 2020 Q1
Q1 2018 $2,903,000 +$441,000 +18% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019 2019 Q1
Q1 2017 $2,462,000 +$2,459,355 01 Jan 2017 31 Mar 2017 10-Q 09 May 2018 2018 Q1
Q1 2016 $2,645* -$2,256,355 01 Jan 2016 31 Mar 2016 10-Q 08 May 2017 2017 Q1
Q1 2015 $2,259,000 +$649,000 +40% 01 Jan 2015 31 Mar 2015 10-Q 09 May 2016 2016 Q1
Q1 2014 $1,610,000 01 Jan 2014 31 Mar 2014 10-Q 08 May 2015 2015 Q1

BIOCRYST PHARMACEUTICALS INC Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $65,413,000 +$9,798,000 +18% 01 Jan 2024 31 Dec 2024 10-K 25 Feb 2025 2024 FY
2023 $55,615,000 +$10,914,000 +24% 01 Jan 2023 31 Dec 2023 10-K 25 Feb 2025 2024 FY
2022 $44,701,000 +$10,061,000 +29% 01 Jan 2022 31 Dec 2022 10-K 25 Feb 2025 2024 FY
2021 $34,640,000 +$19,846,000 +134% 01 Jan 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
2020 $14,794,000 -$2,925,000 -17% 01 Jan 2020 31 Dec 2020 10-K 27 Feb 2023 2022 FY
2019 $17,719,000 +$8,323,000 +89% 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
2018 $9,396,000 -$3,225,000 -26% 01 Jan 2018 31 Dec 2018 10-K 01 Mar 2021 2020 FY
2017 $12,621,000 +$4,134,000 +49% 01 Jan 2017 31 Dec 2017 10-K 13 Mar 2020 2019 FY
2016 $8,487,000 -$1,218,000 -13% 01 Jan 2016 31 Dec 2016 10-K 14 Mar 2019 2018 FY
2015 $9,705,000 -$472,000 -4.6% 01 Jan 2015 31 Dec 2015 10-K 12 Mar 2018 2017 FY
2014 $10,177,000 +$5,809,000 +133% 01 Jan 2014 31 Dec 2014 10-K 27 Feb 2017 2016 FY
2013 $4,368,000 +$201,000 +4.8% 01 Jan 2013 31 Dec 2013 10-K 26 Feb 2016 2015 FY
2012 $4,167,000 01 Jan 2012 31 Dec 2012 10-K 02 Mar 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.